The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted the public to the recall of Mivacron and Nimbex injections over safety concerns.
In a statement on its X handle on Monday, NAFDAC said the products were manufactured by Aspen Pharmacare Asia Limited and that the recall followed safety concerns approved by the Hong Kong Department of Health.
According to the agency, one batch of Mivacron Injection 0.2% and five batches of Nimbex Injection 2mg/mL were affected.
ALSO READ: NHF programme boosts PHC service delivery in FCT
“The recall was made as a precautionary measure due to potential quality issues identified by the manufacturer,” NAFDAC said.
Investigations revealed deficiencies in the manufacturer’s manual visual inspection process. NAFDAC added that “not all glass particles in the ampoules were likely detected,” prompting a voluntary market recall.
The injections, which contain mivacurium and cisatracurium, are prescription medicines used as adjuncts to general anaesthesia.
NAFDAC advised healthcare professionals and consumers to report suspected substandard medicines to its nearest office or via its e-reporting platforms at www.nafdac.gov.ng.
